SCHEMBL15475619

SCHEMBL15475619

Cc1ccc(Br)cc1-c1c(O)cccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.42
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.37
MC4R P32245 1/20 0.37
ELANE P08246 1/20 0.36
CTSG P08311 1/20 0.36
CHEK1 O14757 1/20 0.36
WEE1 P30291 1/20 0.36
AR P10275 1/20 0.36
PLA2G7 Q13093 1/20 0.36
ALDH1A1 P00352 2/20 0.35
BCL2 P10415 1/20 0.35
MCL1 Q07820 1/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
HSD17B2 P37059 1/20 0.34
AGPAT2 O15120 1/20 0.34
TRPA1 O75762 1/20 0.33
BIRC5 O15392 1/20 0.33
PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15475815 0.81 KMT2A (0.39) HSP90AA1MAPTTSHRCHEK1WEE1
SCHEMBL4621499 0.78 ALDH1A1 (0.46) HSP90AA1MAPTTSHRELANECTSG
SCHEMBL23658585 0.73 TSHR (0.42) HSP90AA1MAPTTSHRALDH1A1ESR2
SCHEMBL17399880 0.72 HSP90AA1 (0.49) HSP90AA1MAPTTSHRALDH1A1
SCHEMBL26347192 0.71 ALOX15 (0.48) MAPTTSHRALDH1A1BCL2MCL1
SCHEMBL20983402 0.71 HSP90AA1 (0.51) HSP90AA1TSHRELANECTSGALDH1A1
SCHEMBL20926553 0.71 KMT2A (0.46) MAPTMCL1ALOX15
SCHEMBL890757 0.70 S100A4 (0.46) ALDH1A1BCL2MCL1AGPAT2BIRC5
SCHEMBL277702 0.70 PBRM1 (0.44) MAPTELANEPLA2G7ALDH1A1
SCHEMBL7906592 0.70 TSHR (0.46) HSP90AA1MAPTTSHRCHEK1WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888266-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO 5) LTD (GB) 2017-01-11 EP disclosed
EP-2888266-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO 5) LTD (GB) 2017-01-11 EP disclosed
EP-2888266-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2015-07-01 EP disclosed
US-8906929-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-09 US disclosed
US-8906929-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-09 US disclosed
US-8906929-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-09 US disclosed
US-20140051692-A1 Inhibitors of Human Immunodeficiency Virus Replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2014-02-20 US disclosed
US-20140051692-A1 Inhibitors of Human Immunodeficiency Virus Replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2014-02-20 US disclosed
US-20140051692-A1 Inhibitors of Human Immunodeficiency Virus Replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2014-02-20 US disclosed
WO-2014028384-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2014-02-20 WO disclosed
WO-2014028384-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051692-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS HSP90AA1 2182/4885MAPT 2620/4885TSHR 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.